Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pedanios** is a non-specific trade name used for a portfolio of prescription medical-cannabis dried-flower products, not a single chemically defined drug. The portfolio has included THC-dominant cannabis cultivars such as Pedanios 20/1, whose cannabinoid content, cultivar, cultivation site, and product specifications can vary. Its principal pharmacologically active constituent is generally delta-9-tetrahydrocannabinol, which activates cannabinoid receptors in the endocannabinoid system; cannabidiol and other phytocannabinoids may also be present in variable amounts. Pedanios originated as a German medical-cannabis importer and wholesaler and was acquired by Aurora Cannabis; Aurora subsequently renamed Pedanios GmbH as Aurora Deutschland GmbH. ([newswire.ca](https://www.newswire.ca/news-releases/aurora-acquires-german-medical-cannabis-market-leader-pedanios-gmbh-624649463.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pedanios.